Mark L. Baum, J.D., Founder
Chief Executive Officer, Member, Board of Directors
Mark L. Baum is the founder and CEO of Imprimis Pharmaceuticals, a commercial stage pharmaceutical company focused on providing patients and physicians with innovative and affordable ophthalmic drugs in the ocular surgery, glaucoma, and dry eye disease markets. Mr. Baum is also a founder and board member of Eton Pharmaceuticals, Surface Pharmaceuticals, and Melt Pharmaceuticals. Mr. Baum was named by Ernst & Young LLP as the 2017 Entrepreneur of the Year™ in the life sciences category for the San Diego region. Prior to Imprimis, as the founder of TBLF, LLC, a private investment fund, Mr. Baum made more than 200 investments into more than 40 private and public companies. In 1999, Mr. Baum founded YesRx, an HIV-focused pharmacy business. Mr. Baum’s advocacy for drug pricing and accessibility issues has been featured in Op-Ed contributions for the Wall Street Journal and through appearances on CBS, CNN, MSNBC, Fox Business, Bloomberg and Al Jazeera. Mr. Baum is a 1995 cum laude graduate of The University of Texas at Arlington and a 1997 graduate of California Western School of Law.